Takeda Oncology
Katie Valentino is a highly skilled medical professional with extensive experience in nursing and oncology. Currently serving as a Medical Science Liaison for Solid Tumor at Takeda Oncology since November 2021, Katie also holds the position of Oncology Nurse Liaison at PM Pediatrics. Since March 2018, Katie has worked as an Advanced Practice Nurse in Pediatric Emergency Medicine and Emergency Medicine at UChicago Medicine. Previous roles at Ann & Robert H. Lurie Children’s Hospital of Chicago include Advanced Practice Nurse in Hematology/Oncology Float, Inpatient Oncology, and Neuro-Oncology & Survivorship from March 2015 to April 2021. Katie began her career as a Registered Nurse at UChicago Medicine and La Rabida Children's Hospital and complemented clinical experience with a Doctor of Nursing Practice from The University of Alabama and a Master of Science in Nursing from Loyola University Chicago. Currently pursuing a Post-Graduate Certificate in Psychiatric/Mental Health Nurse Practitioner at the University of Cincinnati, Katie remains committed to advancing healthcare in oncology and emergency medicine.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.